Since SDF-1 pretreatment during EPC expansion stimulates EPC adhesion and increases the efficiency of cell therapy for ischemic vascular diseases, increases EPC number and recruitment of bone marrow-derived EPCs into site of ischemia [38], one can advance the hypothesis that MPsPPARα+/+ can be used as an expansion agent of EPCs. This evidence concerns the gene CXCL12 and ischemia.